Neurobeachin-like protein 2 (NBEAL2)

Homo sapiens — UniProt Q6ZNJ1

Gene: NBEAL2Homo sapiensSwissProt reviewed

Data last refreshed: 2026-04-18 (UniProt release unknown)

Key facts

Neurobeachin-like protein 2 (NBEAL2) is a protein from Homo sapiens identified by UniProt accession Q6ZNJ1, 2754 residues long. MolForge cross-references it against 0 known binders and 310 disease associations.

UniProt accession: Q6ZNJ1; gene symbol NBEAL2.
Organism: Homo sapiens.
Length: 2754 amino acids.
Top disease associations (Open Targets): gray platelet syndrome, Thrombocytopenia and Abnormal bleeding.
3D structure: AlphaFold model available.

Target properties

Protein name	Neurobeachin-like protein 2
UniProt accession	Q6ZNJ1
Gene	NBEAL2
Organism	Homo sapiens
Length	2754 residues
Molecular weight	—
EC numbers	—
Target class	—
Subcellular location	—
Keywords	—

Druggability

Target tractability assessment (Open Targets + pocket analysis). No approved drug

Druggability tier	MEDIUM
Druggability score	—
Pocket score	—
Max clinical phase	—

Disease associations (310)

Diseases linked to this target (Open Targets).

gray platelet syndrome · score 0.82
Thrombocytopenia · score 0.39
Abnormal bleeding · score 0.39
high density lipoprotein cholesterol measurement · score 0.31
mean platelet volume · score 0.29
neutrophil percentage of leukocytes · score 0.28
platelet count · score 0.27
platelet crit · score 0.27
HbA1c measurement · score 0.27
lymphocyte count · score 0.25

3D Structure (8)

Experimental (PDB) and predicted (AlphaFold) structures for this protein.

Structure	Source	Method	Mean pLDDT	Resolution (Å)
AF-Q6ZNJ1-F8	alphafold	PREDICTED	80.96	—
AF-Q6ZNJ1-F7	alphafold	PREDICTED	76.51	—
AF-Q6ZNJ1-F3	alphafold	PREDICTED	75.96	—
AF-Q6ZNJ1-F1	alphafold	PREDICTED	75.90	—
AF-Q6ZNJ1-F6	alphafold	PREDICTED	75.88	—
AF-Q6ZNJ1-F2	alphafold	PREDICTED	75.62	—
AF-Q6ZNJ1-F5	alphafold	PREDICTED	75.06	—
AF-Q6ZNJ1-F4	alphafold	PREDICTED	73.82	—

Experimental structures are not indexed in MolForge yet — search RCSB PDB for Q6ZNJ1.

Amino-acid sequence (2754 residues)

MAASERLYEL WLLYYAQKDL GYLQQWLKAF VGAFKKSISL SSLEPRRPEE AGAEVPLLPL DELHVLAEQL HQADLEQALL LLKLFIILCR NLENIEAGRG QVLVPRVLAL LTKLVAELKG CPPPQGRGTQ LENVALHALL LCEGLFDPYQ TWRRQRSGEV ISSKEKSKYK FPPAALPQEF SAFFQESLQN ADHLPPILLL RLIHLFCAVL AGGKENGQMA VSDGSVKGLL SVVRGWSRGP APDPCLVPLA LEALVGAVHV LHASRAPPRG PELRALLESY FHVLNADWPA GLSSGPEEAL VTLRVSMLDA IPMMLACEDR PVLQATFLSN NCFEHLTRLI QNSKLYLQSR APPEGDSDLA TRLLTEPDVQ KVLDQDTDAI AVHVVRVLTC IMSDSPSAKE VFKERIGYPH LQEVLQSHGP PTHRLLQELL NMAVEGDHSM CPPPPIRNEQ PVLVLAQWLP SLPTAELRLF LAQRLRWLCD SCPASRATCV QAGLVGCLLE TLSTGLALEA RCQEQLLALL QALGRVSIRP MELRHLLRPR PGLDSEPGGA EAGKARHAGA VIRTLSGMAR HQGPARALRY FDLTPSMAGI MVPPVQRWPG PGFTFHAWLC LHPMDTAPTP APTRPLQRKQ LYSFFTSSGS GFEAFFTAAG TLVVAVCTRK EYLTMSLPEV SFADSAWHCV AIVHVPGRRP FSQNLVHVYK DGHLVKTAPL RCPSLSEPFS SCCIGSAGYR TTTTTTGLPT PPVPATLAYT HPALTRSQSV PASTGLGWGS GLVAPLQEGS IDSTLAGTQD TRWGSPTSLE GELGAVAIFH EALQATALRT LCTLGPNETA PFKPEGELHE LSTRLLLHYS PQACKNNICL DLSPSHGLDG RLTGHRVETW DVKDVVNCVG GMGALLPLLE RVAAQPKEAE AGPAETHDLV GPELTSGHNT QGLVLPLGKS SEERMERNAV AAFLLMLRNF LQGHMVNQES LVQCQGPAII GALLRKVPSW AMDMNVLMSA QLLMEQVAAE GSGPLLYLLY QHLLFNFHLW TLSDFAVRLG HIQYMSSIVR EHRQKLRKKY GVQFILDALR THYSPQRERP LAADDLRTVQ TSLLGLAREF LVRSLSADDV QVTQTMLSFL AATGDDGQAV GALDLLLALL HGSLVQESLA VFLLEPGNLE VLLALLVRPG SLPLLPDRVC KILRRLQQNE RLPERSRQRL RLRECGLQGL VACLPEGTVS PQLCQGLYKL FLGADCLNLS DLLAVVQLSL QADLSVRLDI CRQLFHLIYG QPDVVRLLAR QAGWQDVLTR LYVLEAATAG SPPPSSPESP TSPKPAPPKP PTESPAEPSD VFLPSEAPCP DPDGFYHALS PFCTPFDLGL ERSSVGSGNT AGGGGSSGTL TPASQPGTPS PLDGPRPFPA APGRHSSSLS NVLEDGSLPE PTISGDDTSN TSNPQQTSEE ELCNLLTNVL FSVTWRGVEG SDEAAWRERG QVFSVLTQLG ASATLVRPPD CIKRSLLEMM LESALTDIKE APVGVLASLT QQALWLLRLL QDFLCAEGHG NQELWSEKLF EGVCSLLDRL GAWPHLANGT ADLREMAQIG LRLVLGYILL EDPQLHAQAY VRLHMLLQTA VPARREEACY VLSKLEAALG RVLNTSSLES ATDEAGSPLA AAAAAAAAER CSWLVPLVRT LLDRAYEPLG LQWGLPSLPP TNGSPTFFED FQAFCATPEW RHFIDKQVQP TMSQFEMDTY AKSHDLMSGF WNACYDMLMS SGQRRQWERA QSRRAFQELV LEPAQRRARL EGLRYTAVLK QQATQHSMAL LHWGALWRQL ASPCGAWALR DTPIPRWKLS SAETYSRMRL KLVPNHHFDP HLEASALRDN LGEVPLTPTE EASLPLAVTK EAKVSTPPEL LQEDQLGEDE LAELETPMEA AELDEQREKL VLSAECQLVT VVAVVPGLLE VTTQNVYFYD GSTERVETEE GIGYDFRRPL AQLREVHLRR FNLRRSALEL FFIDQANYFL NFPCKVGTTP VSSPSQTPRP QPGPIPPHTQ VRNQVYSWLL RLRPPSQGYL SSRSPQEMLR ASGLTQKWVQ REISNFEYLM QLNTIAGRTY NDLSQYPVFP WVLQDYVSPT LDLSNPAVFR DLSKPIGVVN PKHAQLVREK YESFEDPAGT IDKFHYGTHY SNAAGVMHYL IRVEPFTSLH VQLQSGRFDC SDRQFHSVAA AWQARLESPA DVKELIPEFF YFPDFLENQN GFDLGCLQLT NEKVGDVVLP PWASSPEDFI QQHRQALESE YVSAHLHEWI DLIFGYKQRG PAAEEALNVF YYCTYEGAVD LDHVTDERER KALEGIISNF GQTPCQLLKE PHPTRLSAEE AAHRLARLDT NSPSIFQHLD ELKAFFAEVV SDGVPLVLAL VPHRQPHSFI TQGSPDLLVT VSASGLLGTH SWLPYDRNIS NYFSFSKDPT MGSHKTQRLL SGPWVPGSGV SGQALAVAPD GKLLFSGGHW DGSLRVTALP RGKLLSQLSC HLDVVTCLAL DTCGIYLISG SRDTTCMVWR LLHQGGLSVG LAPKPVQVLY GHGAAVSCVA ISTELDMAVS GSEDGTVIIH TVRRGQFVAA LRPLGATFPG PIFHLALGSE GQIVVQSSAW ERPGAQVTYS LHLYSVNGKL RASLPLAEQP TALTVTEDFV LLGTAQCALH ILQLNTLLPA APPLPMKVAI RSVAVTKERS HVLVGLEDGK LIVVVAGQPS EVRSSQFARK LWRSSRRISQ VSSGETEYNP TEAR

External references

UniProt AlphaFold QuickGO RCSB PDB GeneCards

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

Which diseases are associated with NBEAL2?

The strongest Open Targets associations for NBEAL2 are gray platelet syndrome, Thrombocytopenia, Abnormal bleeding, high density lipoprotein cholesterol measurement and mean platelet volume.

How long is the NBEAL2 protein?

The Homo sapiens NBEAL2 protein (UniProt Q6ZNJ1) is 2754 amino acids long.

Browse: Targets: N · all protein targets A–Z · drugs A–Z.

Sources

UniProtKB Q6ZNJ1 — name, gene, function, sequence, keywords (CC BY 4.0)
AlphaFold DB Q6ZNJ1 — predicted 3D structure (CC BY 4.0)
Open Targets Platform — disease associations and tractability (CC0)

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.